HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please email our help desk at Readiness Help

Prime Recipient Report

Award Detail for: 3D HUMAN SKIN MODELS
Recipient Name:WISTAR INSTITUTE
DUNS Number: 075524595
36TH AT SPRUCE
PHILADELPHIA, PA 19104

Reporting Information

Award Type*: Grant

Award Number*: 1RC1ES018210-01

Final Report*: Recipient responsible for this data

Award Recipient Information

Recipient DUNS Number*: 075524595

Recipient Account Number: Recipient responsible for this data

Recipient Congressional District*: 1

Award Information

Funding Agency Code*: 7529

Awarding Agency Code*:7529

Award Date*: 09-21-2009

Amount of Award*: $ 487,225

Program Source (TAS)*: 750863

CFDA Number*: 93.701

Sub Account Number for Program Source (TAS)*: Recipient responsible for this data

Total Number of Sub Awards to Individuals*: Recipient responsible for this data

Total Amount of Sub Awards to Individuals*: Recipient responsible for this data

Total Number of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Amount of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Number of Sub Awards less than $25,000/award*: Recipient responsible for this data

Total Amount of Sub Awards less than $25,000/award*: Recipient responsible for this data

Award Description* DESCRIPTION (provided by applicant): This project addresses 3D or virtual models to reduce the use of animals in research: Creation of miniature multi-cellular organs for high-throughput screening for chemical toxicity testing. Our long-term objective is to decrease the use of animals for toxicity assays and increase the use of human cells for toxicity and safety assessment. We will establish a three-dimensional (3D) model of the normal human skin to create experimental conditions that are more 'human-specific' and more predictive with the added benefit of decreasing the number of animals required for preclinical toxicology and safety assessment. Mouse skin is significantly different from human skin in its architecture and varies in response to environmental toxins (biological origin) and xenobiotics (synthetic chemicals). Our working hypothesis is that 3D reconstructed human skin can be used as a reliable system to screen for the effects of xenobiotic exposures. The murine epidermis is very thin and largely devoid of melanocytes, whereas human epidermis is thick and contains pigment-producing melanocytes. Major carcinogens for mouse skin such as DMBA and the phorbol ester PMA/TPA commonly used in classical two-stage carcinogenesis studies in mice show little effect on human skin grafted to immunodeficient animals. To better determine which xenobiotics are affecting human cells, we will reconstruct in vitro human skin containing two layers: 1) 'dermis' consisting of fibroblasts and, optionally, also endothelial, smooth muscle, and inflammatory, and immune cells that are all embedded in collagen type I; 2) 'epidermis' consisting of multilayered keratinocytes at distinct differentiation stages and melanocytes, which reside in the basal layer and attach to the developing basement membrane. Synthetic human skin (also termed skin reconstructs or organotypic skin) contains at least three cell types (fibroblasts, melanocytes, keratinocytes) and up to six additional cell types (e.g., including endothelial cells, smooth muscle cells, and inflammatory cells), and the structures and functions generated are similar to intact, full-thickness human skin. Our specific objectives are: Specific Aim 1. Test human skin reconstructs of various complexities and develop parameters for detecting skin cell damage after exposure to xenobiotics. As parameters for measures of toxicity, we will use cell viability or death, changes in differentiation patterns for keratinocytes, melanocytes, and endothelial cells, and for long-term effects changes in markers associated with transformation. Specific Aim 2. Miniaturize reconstructs to 96-well format and establish standardized criteria for medium-to-high throughput testing. The human skin reconstructs will be established in 96-well plate format and we will perform side-by-side comparison of the in vitro models with the orthotropic human and the murine skin models to compare sensitivity, reproducibility, and interpretability of large-scale 3D testing of xenobiotics. Public Health Relevance Statement These studies aim to establish a three-dimensional (3D) model of the normal human skin to create experimental conditions that are more 'human-specific' and more predictive with the added benefit of decreasing the number of animals required for preclinical toxicology and safety assessment. We will perform side-by-side comparison of the in vitro models with the orthotropic human and the murine skin models to compare sensitivity, reproducibility, and interpretability of large-scale 3D testing of xenobiotics.

Project Information

Project Name or Project/Program Title*: 3D HUMAN SKIN MODELS

Project Status*: Recipient responsible for this data

Total Federal Amount of ARRA Funds Received/Invoiced*: Recipient responsible for this data

Number of Jobs*: Recipient responsible for this data

Description of Jobs Created*: Recipient responsible for this data

Quarterly Activities/Project Description*: Recipient responsible for this data

Activity Code (NAICS or NTEE-NPC)*: Recipient responsible for this data

Total Federal Amount of ARRA Expenditure* (Enter the cumulative total amount of Recovery Funds received that were expended to projects or activities. Refer to the Data Model for details on how to calculate this amount.): Recipient responsible for this data

Total Federal ARRA Infrastructure Expenditure Recipient responsible for this data

Infrastructure Contact Name: Recipient responsible for this data

Infrastructure Contact Email: Recipient responsible for this data

Infrastructure Contact Phone: Recipient responsible for this data

Infrastructure Contact Phone Ext: Recipient responsible for this data

Infrastructure Contact Street Address 1: 36TH AT SPRUCE

Infrastructure Contact Street Address 2: Not Available

Infrastructure Contact Street Address 3: Recipient responsible for this data

Infrastructure City: PHILADELPHIA

Infrastructure State: PA

Infrastructure ZIP Code+4: 19104

Infrastructure Purpose and Rationale (If applicable, enter an explanation about how the infrastructure investment will contribute to one or more purposes of the Recovery Act. Refer to the Data Model for details on what to report. 4000 characters or less.): Recipient responsible for this data

Primary Place of Performance

Street Address 1: Not Available

Street Address 2: PHILADELPHIA

City*: PHILADELPHIA

State*: PA

ZIP Code+4*: 191044265

Congressional District*: 2

Country*: US

Recipient Highly Compensated Officers

Prime Recipient Indication of Reporting Applicability*: Recipient responsible for this data

1. Officer Name and Compensation: Recipient responsible for this data
2. Officer Name and Compensation: Recipient responsible for this data
3. Officer Name and Compensation: Recipient responsible for this data
4. Officer Name and Compensation: Recipient responsible for this data
5. Officer Name and Compensation: Recipient responsible for this data

This concludes the current search. To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool Landing Page.